Vaccine protection by a triple deletion mutant of simian immunodeficiency virus

Michael S. Wyand, Kelledy H. Manson, Maria Garcia-Moll, David Montefiori, Ronald Charles Desrosiers

Research output: Contribution to journalArticle

284 Citations (Scopus)

Abstract

Twelve rhesus monkeys were vaccinated with SIVmac316Δnef (lacking nef sequences), and 12 were vaccinated with SIVmac239Δ3 (lacking nef, vpr, and upstream sequences in U3). SIVmac316 and SIVmac239 differ by only eight amino acids in the envelope; these changes render SIVmac316 highly competent for replication in macrophages. Seventeen of the animals developed persistent infections with the vaccine viruses. Seven of the 24 vaccinated animals, however, developed infections that were apparently transient in nature. Six of these seven yielded virus from peripheral blood when tested at weeks 2 and/or 3, three of the seven had transient antibody responses, but none of the seven had persisting antibody responses. The 24 monkeys were challenged in groups of four with 10 rhesus monkey infectious doses of wild-type, pathogenic SIVmac251 at weeks 8, 20, and 79 following receipt of vaccine. None of the seven with apparently transient infections with vaccine virus were protected upon subsequent challenge. Analysis of cell-associated viral loads, CD4+ cell counts, and viral gene sequences present in peripheral blood in the remainder of the monkeys following challenge allowed a number of conclusions. (i) There was a trend toward increased protection with length of time of vaccination. (ii) Solid vaccine protection was achieved by 79 weeks with the highly attenuated SIV239Δ3. (iii) Solid long-term protection was achieved in at least two animals in the absence of complete sterilizing immunity. (iv) Genetic backbone appeared to influence protective capacity; animals vaccinated with SIV239Δ3 were better protected than animals receiving SIV316Δnef. This better protection correlated with increased levels of the replicating vaccine strain. (v) The titer of virus-neutralizing activity in serum on the day of challenge correlated with protection when measured against a primary stock of SIVmac251 but not when measured against a laboratory-passaged stock. The level of binding antibodies to whole virus by enzyme-linked immunosorbent assay also correlated with protection.

Original languageEnglish (US)
Pages (from-to)3724-3733
Number of pages10
JournalJournal of Virology
Volume70
Issue number6
StatePublished - 1996
Externally publishedYes

Fingerprint

Simian immunodeficiency virus
Simian Immunodeficiency Virus
Vaccines
vaccines
mutants
Viruses
viruses
animals
viral load
Macaca mulatta
Viral Load
antibodies
Antibody Formation
Haplorhini
monkeys
Infection
infection
Viral Genes
blood
CD4 Lymphocyte Count

ASJC Scopus subject areas

  • Immunology

Cite this

Wyand, M. S., Manson, K. H., Garcia-Moll, M., Montefiori, D., & Desrosiers, R. C. (1996). Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. Journal of Virology, 70(6), 3724-3733.

Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. / Wyand, Michael S.; Manson, Kelledy H.; Garcia-Moll, Maria; Montefiori, David; Desrosiers, Ronald Charles.

In: Journal of Virology, Vol. 70, No. 6, 1996, p. 3724-3733.

Research output: Contribution to journalArticle

Wyand, MS, Manson, KH, Garcia-Moll, M, Montefiori, D & Desrosiers, RC 1996, 'Vaccine protection by a triple deletion mutant of simian immunodeficiency virus', Journal of Virology, vol. 70, no. 6, pp. 3724-3733.
Wyand, Michael S. ; Manson, Kelledy H. ; Garcia-Moll, Maria ; Montefiori, David ; Desrosiers, Ronald Charles. / Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. In: Journal of Virology. 1996 ; Vol. 70, No. 6. pp. 3724-3733.
@article{02b84a2b08bb4e7a8bcb5b4e24f67ef0,
title = "Vaccine protection by a triple deletion mutant of simian immunodeficiency virus",
abstract = "Twelve rhesus monkeys were vaccinated with SIVmac316Δnef (lacking nef sequences), and 12 were vaccinated with SIVmac239Δ3 (lacking nef, vpr, and upstream sequences in U3). SIVmac316 and SIVmac239 differ by only eight amino acids in the envelope; these changes render SIVmac316 highly competent for replication in macrophages. Seventeen of the animals developed persistent infections with the vaccine viruses. Seven of the 24 vaccinated animals, however, developed infections that were apparently transient in nature. Six of these seven yielded virus from peripheral blood when tested at weeks 2 and/or 3, three of the seven had transient antibody responses, but none of the seven had persisting antibody responses. The 24 monkeys were challenged in groups of four with 10 rhesus monkey infectious doses of wild-type, pathogenic SIVmac251 at weeks 8, 20, and 79 following receipt of vaccine. None of the seven with apparently transient infections with vaccine virus were protected upon subsequent challenge. Analysis of cell-associated viral loads, CD4+ cell counts, and viral gene sequences present in peripheral blood in the remainder of the monkeys following challenge allowed a number of conclusions. (i) There was a trend toward increased protection with length of time of vaccination. (ii) Solid vaccine protection was achieved by 79 weeks with the highly attenuated SIV239Δ3. (iii) Solid long-term protection was achieved in at least two animals in the absence of complete sterilizing immunity. (iv) Genetic backbone appeared to influence protective capacity; animals vaccinated with SIV239Δ3 were better protected than animals receiving SIV316Δnef. This better protection correlated with increased levels of the replicating vaccine strain. (v) The titer of virus-neutralizing activity in serum on the day of challenge correlated with protection when measured against a primary stock of SIVmac251 but not when measured against a laboratory-passaged stock. The level of binding antibodies to whole virus by enzyme-linked immunosorbent assay also correlated with protection.",
author = "Wyand, {Michael S.} and Manson, {Kelledy H.} and Maria Garcia-Moll and David Montefiori and Desrosiers, {Ronald Charles}",
year = "1996",
language = "English (US)",
volume = "70",
pages = "3724--3733",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - Vaccine protection by a triple deletion mutant of simian immunodeficiency virus

AU - Wyand, Michael S.

AU - Manson, Kelledy H.

AU - Garcia-Moll, Maria

AU - Montefiori, David

AU - Desrosiers, Ronald Charles

PY - 1996

Y1 - 1996

N2 - Twelve rhesus monkeys were vaccinated with SIVmac316Δnef (lacking nef sequences), and 12 were vaccinated with SIVmac239Δ3 (lacking nef, vpr, and upstream sequences in U3). SIVmac316 and SIVmac239 differ by only eight amino acids in the envelope; these changes render SIVmac316 highly competent for replication in macrophages. Seventeen of the animals developed persistent infections with the vaccine viruses. Seven of the 24 vaccinated animals, however, developed infections that were apparently transient in nature. Six of these seven yielded virus from peripheral blood when tested at weeks 2 and/or 3, three of the seven had transient antibody responses, but none of the seven had persisting antibody responses. The 24 monkeys were challenged in groups of four with 10 rhesus monkey infectious doses of wild-type, pathogenic SIVmac251 at weeks 8, 20, and 79 following receipt of vaccine. None of the seven with apparently transient infections with vaccine virus were protected upon subsequent challenge. Analysis of cell-associated viral loads, CD4+ cell counts, and viral gene sequences present in peripheral blood in the remainder of the monkeys following challenge allowed a number of conclusions. (i) There was a trend toward increased protection with length of time of vaccination. (ii) Solid vaccine protection was achieved by 79 weeks with the highly attenuated SIV239Δ3. (iii) Solid long-term protection was achieved in at least two animals in the absence of complete sterilizing immunity. (iv) Genetic backbone appeared to influence protective capacity; animals vaccinated with SIV239Δ3 were better protected than animals receiving SIV316Δnef. This better protection correlated with increased levels of the replicating vaccine strain. (v) The titer of virus-neutralizing activity in serum on the day of challenge correlated with protection when measured against a primary stock of SIVmac251 but not when measured against a laboratory-passaged stock. The level of binding antibodies to whole virus by enzyme-linked immunosorbent assay also correlated with protection.

AB - Twelve rhesus monkeys were vaccinated with SIVmac316Δnef (lacking nef sequences), and 12 were vaccinated with SIVmac239Δ3 (lacking nef, vpr, and upstream sequences in U3). SIVmac316 and SIVmac239 differ by only eight amino acids in the envelope; these changes render SIVmac316 highly competent for replication in macrophages. Seventeen of the animals developed persistent infections with the vaccine viruses. Seven of the 24 vaccinated animals, however, developed infections that were apparently transient in nature. Six of these seven yielded virus from peripheral blood when tested at weeks 2 and/or 3, three of the seven had transient antibody responses, but none of the seven had persisting antibody responses. The 24 monkeys were challenged in groups of four with 10 rhesus monkey infectious doses of wild-type, pathogenic SIVmac251 at weeks 8, 20, and 79 following receipt of vaccine. None of the seven with apparently transient infections with vaccine virus were protected upon subsequent challenge. Analysis of cell-associated viral loads, CD4+ cell counts, and viral gene sequences present in peripheral blood in the remainder of the monkeys following challenge allowed a number of conclusions. (i) There was a trend toward increased protection with length of time of vaccination. (ii) Solid vaccine protection was achieved by 79 weeks with the highly attenuated SIV239Δ3. (iii) Solid long-term protection was achieved in at least two animals in the absence of complete sterilizing immunity. (iv) Genetic backbone appeared to influence protective capacity; animals vaccinated with SIV239Δ3 were better protected than animals receiving SIV316Δnef. This better protection correlated with increased levels of the replicating vaccine strain. (v) The titer of virus-neutralizing activity in serum on the day of challenge correlated with protection when measured against a primary stock of SIVmac251 but not when measured against a laboratory-passaged stock. The level of binding antibodies to whole virus by enzyme-linked immunosorbent assay also correlated with protection.

UR - http://www.scopus.com/inward/record.url?scp=0029951823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029951823&partnerID=8YFLogxK

M3 - Article

C2 - 8648707

AN - SCOPUS:0029951823

VL - 70

SP - 3724

EP - 3733

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 6

ER -